Anxiety disorders are widely prevalent but insufficiently recognized and inadequately treated in primary care practice. The annual costs of morbidity and mortality of these disorders approach $50 billion, substantially more than costs for schizophrenia or all affective disorders combined. Somatization of anxiety contributes to the challenges of making an accurate diagnosis and to the indirect costs associated with delaying appropriate treatment. Pharmacologic interventions give clinicians the necessary tools to treat anxiety safely and effectively. Former therapeutic choices were limited to benzodiazepines, buspirone, and older antidepressants, but newer anxiolytic agents, but newer anxiolytic agents have become available. The selective serotonin reuptake inhibitors and agents with dual reuptake inhibition, such as venlafaxine XR, are optimizing therapy and yielding less risk for serious adverse events, greater safety in long-term therapy, and opportunity for improved patient compliance. These newer antidepressants provide substantial efficacy in patients with comorbid anxiety and depression, commonly seen in the primary care setting.

(Primary Care Companion J Clin Psychiatry 2000;2:49-54)
general, patients with anxiety fare substantially worse than patients with other psychiatric conditions, such as depression, even when they receive an accurate diagnosis and appropriate treatment. Because both anxiety and depression commonly manifest as nonspecific distress (e.g., mild sleep or appetite disturbances), it is not unusual for anxious patients seen in the primary care setting to receive a misdiagnosis of depression. This finding is further complicated by the fact that patients with longstanding anxiety may develop symptoms of depression over time. However, anxiety disorders generally can be distinguished from depressive states. In anxiety states, increased vasomotor responsiveness, as well as panic attacks, phobias, derealization, and perceptual dysfunctions, are frequently seen. In contrast, the general affect in depression is mostly negative, often associated with loss of interest and pleasure (anhedonia), hopelessness, emotional withdrawal, and fatigue. However, as we shall see, the diagnostic distinction between anxiety disorders and depression has become less important as the treatments have become more similar.

### SOMATIZATION OF ANXIETY AMONG PRIMARY CARE PATIENTS

Somatization refers to the phenomenon in which patients experience and express their feelings or emotions through physical complaints and distress. This phenomenon may result from a variety of cultural, familial, and personal circumstances, including biases against expressing psychological discomfort. Patients may fear being stigmatized if they are labeled with a psychiatric disorder, or they may be concerned about their physician’s response to nonsomatic complaints. Although the term somatization is generally used, it needs to be differentiated from somatization disorder, which is recognized as a distinct clinical psychiatric disorder. A study in 425 primary care patients found that anxiety disorders were associated with a significantly higher rate of comorbid somatization disorder than that observed in the absence of anxiety disorders.

Symptoms typically associated with somatization of anxiety and other psychiatric disorders include abdominal pain, dyspepsia, chest pain, fatigue, dizziness, insomnia, and headache. Such symptoms, occurring either alone or in various combinations, are among the most common reasons for nearly half of all primary care visits among the general population. A study in 1000 primary care patients found that at least 1 of these symptoms was reported by 38% of the patients, but in only 16% did the symptoms correlate with an organic disease over a 3-year period. Other data, also derived from a primary care population, suggested a strong association between the number of medically unexplained symptoms experienced by patients and the likelihood of a concurrent anxiety or depressive disorder. For example, if 7% of patients with 2 or 3 physical symptoms were found to have a diagnosable anxiety disorder, the incidence almost doubled (13%) in those with 4 or 5 somatic complaints and increased to 48% in patients with 9 or more physical symptoms.

In the primary care setting, somatization of anxiety has important implications for identifying patients who have an anxiety disorder. It has been estimated that as many as 53% of patients who meet the criteria for a psychiatric disorder may receive an incorrect diagnosis in this setting. Clinicians may falsely attribute the somatic complaints to an underlying medical condition or, when diagnostic tests reveal no organic cause for the symptoms, may fail to look for a psychiatric cause. In a study conducted in Great Britain, primary care physicians were able to diagnose anxiety, depression, or both significantly more often in patients who had psychiatric symptoms than in patients who had only somatic complaints. A similar study in the United States showed that only 22% of anxious or depressed patients with somatic manifestations received correct diagnoses by their family physicians, compared with 77% of patients who had psychiatric symptoms. These data suggest that patients’ somatic complaints may often lead to an overlooked diagnosis of anxiety as the primary source of the discomfort.

Another confounding factor in the timely and accurate diagnosis of anxiety is the high rate of medical and psychiatric comorbidity in patients with anxiety. Depression may occur in as many as 60% of patients with GAD or panic disorder. In some cases, this comorbidity may manifest as mixed anxiety-depression, a condition that is characterized by subsyndromal levels of both anxiety and depression. Comorbid anxiety and depression is associated with significantly greater psychopathology and early withdrawal from treatment than either disorder alone. In addition, coexisting depression and anxiety portends a worse prognosis, with less robust responses to treatment and a greater risk of suicide, than either disorder alone.

Aside from the presence of unexplained somatic complaints and the high rate of psychiatric comorbidities, anxiety is also frequently associated with comorbid medical illnesses. Anxiety itself may be a factor in provoking or maintaining medical conditions or diseases.
of primary care patients found that those who experienced panic attacks had a significantly higher rate of hypertension than those who did not.13 Left untreated, anxiety may prolong or worsen a medical illness.21

Not surprisingly, undiagnosed or misdiagnosed anxiety is a major contributor to high use of health care resources and excessive health care costs, even after adjusting for comorbid medical conditions.22 Data collected in 1990 indicated that the total costs of anxiety disorders in the United States, including direct costs for hospitalizations and professional services and indirect costs related to morbidity and mortality, reached approximately $46 billion, one third of the total cost for all mental disorders.23 These costs associated with anxiety disorders were higher than those for schizophrenia ($32 billion), affective disorders ($30 billion), and other combined mental disorders ($38 billion). The greatest proportion of the cost of anxiety (nearly three quarters) is attributed to lost or reduced productivity, and the remainder is attributed to the direct costs of medical treatment.24

Somatization also contributes to the high cost of anxiety. Medical workups can be extensive and delay treatment of symptoms. Anxious patients may undergo unnecessary tests or procedures and be referred to various medical specialists before an appropriate psychiatric consultation is sought or a diagnosis is made.13 High users of health care resources are substantially more likely to have an underlying anxiety disorder: as many as 40% have a lifetime history of GAD, and 20% have somatization disorder.24 High medical-resource utilization and overall costs may be especially problematic in patients with panic disorder because of the somatic symptoms such as tachycardia and hypertension associated with a panic attack. These patients are often referred for costly cardiovascular or neurologic tests such as Holter monitoring, exercise testing, angiography, magnetic resonance imaging, or electroencephalography.12 In addition, the use of health care resources and loss of productivity are significantly higher in patients with an anxiety disorder and a comorbid medical or psychiatric condition.25 Therefore, prompt recognition and treatment of anxiety by the primary care physician would help reduce the total cost associated with this disorder.

**TREATING ANXIETY: OPTIONS FOR THE PRIMARY CARE PHYSICIAN**

For many years, pharmacologic therapy for anxiety disorders was dominated by the use of BZDs, buspirone, the older tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).26–34 More recently, newer types of antidepressants have emerged as promising alternatives for the treatment of anxiety, as a result of their robust efficacy (particularly in patients with comorbid anxiety and depression), improved safety profiles, and ease of use.33,35–44 The following sections review these agents from a clinical perspective on dose-response potential, drug-drug interaction profiles, and adverse effects.

**Traditional Anxiolytic Agents**

**Benzodiazepines.** The BZDs have a rapid onset of action, which becomes clinically apparent within the first week of therapy.28 Many currently available BZDs appear to have equivalent anxiolytic efficacy.27 However, many clinicians favor drugs with relatively short half-lives—such as alprazolam, lorazepam, and oxazepam—over longer-acting agents because of their lower risk of sedation, psychomotor impairment (an effect that is enhanced by the intake of alcohol), and amnesic effects, probably as a result of less drug accumulation.26,27 On the other hand, drugs with long half-lives are less likely to produce an intense discontinuation syndrome, a well-characterized reaction in patients who stop therapy with BZDs, which may include symptoms such as rebound anxiety, nervousness, insomnia, restlessness, and depression.26,28,29 The duration of therapy and the rate at which the dosage is tapered off appear to contribute to the likelihood or severity of withdrawal symptoms.29 These effects substantially limit the use of BZDs in the primary care setting. Physical dependence and pharmacologic tolerance are additional risks of therapy with BZDs, particularly over the long term. Therefore, continuous treatment with BZDs requires clinical reevaluation for gradual reduction and discontinuation.27,29

Aside from alprazolam, for which higher plasma concentrations correlate with improved clinical response, no clear dose response has been demonstrated for the BZDs. Typical dosage ranges for healthy adults are 0.75 to 4.0 mg/day for alprazolam (doses of 1.5–10 mg/day are often used in patients with panic disorder), 2 to 6 mg/day for lorazepam, and 30 to 120 mg/day for oxazepam.27 Therapy should be initiated at the lowest possible dosage, to minimize the risk of adverse effects, and should be tailored to patients’ clinical and medication history, age, body size, and state of physical health.27

The duration of treatment and the dosing pattern also should be individualized. Once-daily dosing would encourage patients to comply better with treatment. Intermittent therapy may be adequate in patients with intermittent symptoms or symptoms triggered by identifiable anxiety-provoking situations. Patients experiencing persistent symptoms characteristic of an anxiety disorder, such as GAD, may require more sustained courses of therapy27 with an agent carefully selected for its efficacy and safety properties for each individual patient.45 Particular care should be exercised when using BZDs in older patients and those with organ dysfunction. Drug clearance of longer-acting agents may be impaired with age, hepatic disease, or the concomitant use of estrogens or cimetidine.26
Buspirone. Since buspirone became available in the late 1980s, it has been used as an alternative to BZDs in certain patients. This agent appears to be somewhat more effective in reducing the psychological symptoms of anxiety than it is in treating somatic complaints, and it appears to have dose-related effects. The average therapeutic dosage is 20 to 30 mg/day. Buspirone has a slow onset of action (as long as 4 weeks for full therapeutic effect), and its anxiolytic efficacy is unclear in patients with panic disorder and reduced in those recently withdrawn from BZD therapy.

However, buspirone is more suitable than BZDs for the treatment of chronically anxious patients. The starting dosage should be low (5 mg) and given on a 3-times-daily schedule, with incremental increases every few days. Generally, initial aggressive dosing may result in headache, dizziness, and nausea—common reasons why patients stop their medication prematurely. Although buspirone has an overall more favorable safety profile than the BZDs, drug discontinuation rates after 6 months are higher with buspirone, suggesting less patient satisfaction. Finally, as with the BZDs, care should be taken to avoid drug-drug interactions with buspirone: levels of diazepam or haloperidol may increase during concomitant therapy, and levels of buspirone may increase in the presence of cimetidine and in patients with renal disease.

Tricyclic antidepressants and monoamine oxidase inhibitors. The TCAs and MAOIs also have been used successfully in patients with anxiety, particularly in panic disorder and in those with coexisting depression. Their overall use in primary care, however, is limited by their associated adverse events, safety issues in terms of lethality in overdose, and, particularly with the MAOIs, significant adverse interactions with foods and drugs. The TCAs are associated with notable anticholinergic side effects such as dry mouth, blurred vision, and constipation, which generally do not abate during therapy. Patients often find these effects intolerable and may discontinue treatment as a result. Because TCAs can cause agitation in anxious patients, initial dosages should be very low. In addition, their use in anxious patients with suicidal tendencies should be avoided because of their potential for lethal overdosing—amounts as small as a 1-week’s supply of amitriptyline or imipramine can be lethal.

Newer Antidepressants in the Treatment of Anxiety
The selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in the treatment of anxiety disorders, particularly panic disorder and comorbid anxiety and depression, although their acceptance by the clinical community preceded the results of formal research to demonstrate their anxiolytic efficacy. The more favorable safety and tolerability profiles of the SSRIs are responsible for their preference over the TCAs and MAOIs.

A growing body of data now suggests that venlafaxine extended release (XR), which acts by blocking the reuptake of both serotonin and norepinephrine, is also efficacious for treating patients with an anxiety disorder and, possibly, mixed anxiety-depression. Short- and long-term studies in patients meeting DSM-IV criteria for GAD showed venlafaxine XR to be more effective than placebo and, to a statistically significant degree, buspirone. Venlafaxine XR appears to have one of the most favorable drug-drug interaction profiles relative to those of other antidepressants because it lacks any significant inhibitory effect on the cytochrome P450 isoenzyme system.

In general, these newer antidepressants are considerably safer than the BZDs in sedative effects, withdrawal liability, and psychomotor impairment, and they lack the anticholinergic effects and risk of overdosage of the TCAs. Nausea, headache, insomnia, and somnolence (usually transient) are among the most prominent adverse events noted with these agents. In addition to these effects, some sexual dysfunction has been reported with the use of many of the newer antidepressants. On the other hand, the use of some SSRIs, such as fluoxetine, has been associated with paradoxic anxiety, jitteriness, and nervousness, which may require a short course of therapy with a BZD or starting with a low dosage of the SSRI.

In efficacy, the SSRIs appear to be equivalent to the TCAs in treating anxiety. As is the case with the TCAs and buspirone, the SSRIs are associated with a delay in the onset of activity. Evidence also indicates that the SSRIs may reduce the psychological symptoms of anxiety without improving the somatic symptoms. In contrast, data from studies have shown that venlafaxine XR significantly improves both psychological and somatic symptoms of anxiety in patients with GAD alone and in those with comorbid anxiety and depression, suggesting that this agent may be particularly useful in patients with these types of anxiety disorders. Both the SSRIs and venlafaxine XR can be taken once daily, which enhances convenience for patients, increasing their compliance and possibly increasing their ability to achieve remission and full resolution of symptoms.

CONCLUSIONS
Primary care physicians have an ever-widening array of pharmacologic therapies to use in treating patients with anxiety or mixed anxiety-depression. Compared with the standard anxiolytic agents, the newer antidepressants offer a number of important advantages in this setting. Agents such as the SSRIs and dual reuptake inhibitors are safer in overdosage, more pharmacologically suited to treating anxiety and mixed anxiety-depression, and better tolerated than the older agents. The character-
istics of individual agents that may help guide clinical decisions about which agent to use for a particular patient include the risk of drug-drug interactions, specific side effect profiles, and the presence of coexisting medical or psychiatric disorders.

Drug names: alprazolam (Xanax and others), amitriptyline (Elavil and others), buspirone (BuSpar), cimetidine (Tagamet and others), diazepam (Valium and others), fluoxetine (Prozac), haloperidol (Haldol and others), lorazepam (Ativan and others), oxazepam (Serax and others), venlafaxine XR (Effexor XR).

REFERENCES

52. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on
in adult patients with generalized anxiety disorder. Psychopharmacol Bull
1996;32:671–676
1996;16(3, suppl 2):29S–36S
55. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and toler-
ability of once-daily venlafaxine extended release (XR) in outpatients with
56. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alpra-
zolam and imipramine in generalized anxiety disorder: somatic versus
57. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venla-
faxine extended release (XR) for symptoms of anxiety in depressed outpa-